Respiratory medicine company Propeller Health stated on Thursday that it has passed the International Organization for Standardization (ISO) 13485:2016 certification for medical device quality management systems,
The ISO certification confirms the company is providing the best quality management systems and regulatory compliance for sensors, apps as well as services.
According to the company, the US FDA-cleared medical devices include sensors that attach to inhalers and mobile apps powered by a robust analytics platform helping patients better manage their asthma and COPD symptoms. The clinician tools are used by providers to help improve care and treatment and strengthen relationship with patients.
ISO is an independent, non-governmental international organisation with a membership of 162 national standards bodies based in Geneva, Switzerland. The 13485:2016 is the latest update to the ISO criteria, which was previously revised in 2003.
To achieve certification, the company spent six months undergoing independent review of the processes, documentation and general culture of quality in accordance with ISO guidelines. The ISO certification builds on the US FDA's quality management system principles and is recognised internationally.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval